Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Panel puts Fibrogen project to an almost certain death
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…
Amgen follows Sanofi into a new dermatitis mechanism
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
Sanofi makes a pre-JP Morgan splash with Kymab
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Disaster strikes for Akebia
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
